A novel PP2A enhancer induces caspase-independent apoptosis of MKN28 gastric cancer cells with high MEK activity

Cancer Letters

Volumn 347, Issue 1, 2014, Pages 123-128

  Tsuchiya, Ayako ^a   Kanno, Takeshi ^a   Shimizu, Tadashi ^a   Nakao, Syuhei ^a   Tanaka, Akito ^a   Tabata, Chiharu ^a   Nakano, Takashi ^a   Nishizaki, Tomoyuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Cancer cell; Caspase independent apoptosis; MEK; Phosphatidylinositol derivative; Protein phosphatase 2A

Indexed keywords

1,2 O BIS[8 (2 (2 PENTYL CYCLOPROPYLMETHYL)CYCLOPROPYL)OCTANOYL] SN GLYCERO 3 PHOSPHATIDYL DEXTRO 1 INOSITOL; ANTINEOPLASTIC AGENT; CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; DNA NUCLEOTIDYLEXOTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL FREE SYSTEM; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; ENHANCER REGION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEPATOMA CELL; HUMAN; HUMAN CELL; KIDNEY CANCER; LUNG CANCER; NICK END LABELING; PRIORITY JOURNAL; STOMACH CANCER;

CANCER CELL; CASPASE-INDEPENDENT APOPTOSIS; MEK; PHOSPHATIDYLINOSITOL DERIVATIVE; PROTEIN PHOSPHATASE 2A;

APOPTOSIS; CASPASES; CELL LINE, TUMOR; HUMANS; IN SITU NICK-END LABELING; MAP KINASE KINASE KINASES; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; STOMACH NEOPLASMS;

EID: 84897082995     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.01.034     Document Type: Article

References (17)

1. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
2. Di Paolo G., De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nat. Rev. 2006, 443:651-657.
3. Balla T., Szentpetery Z., Kim Y.J. Phosphoinositide signaling: new tools and insights. Physiology 2009, 24:231-244.
4. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992, 258:607-614.
5. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 1995, 9:484-496.
6. Tanaka A., Nishizaki T. The newly synthesized linoleic acid derivative FR236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors. Bioorg. Med. Chem. Lett. 2002, 13:1037-1040.
7. Kanno T., Yamamoto H., Yaguchi T., Hi R., Mukasa T., Fujikawa H., Nagata T., Yamamoto S., Tanaka A., Nishizaki T. The linoleic acid derivative DCP-LA selectively activates PKC-e{open}, possibly binding to the phosphatidylserine binding site. J. Lipid Res. 2006, 47:1146-1156.
8. Shimizu T., Kanno T., Tanaka A., Nishizaki T. α,β-DCP-LA selectively activates PKC-e{open} and stimulates neurotransmitter release with the highest potency among 4 diastereomers. Cell. Physiol. Biochem. 2011, 27:149-158.
9. Kanno T., Tsuchiya A., Shimizu T., Nakao S., Tanaka A., Nishizaki T. Effects of newly synthesized DCP-LA-phospholipids on protein kinase C and protein phosphatases. Cell. Physiol. Biochem. 2013, 31:555-664.
10. Kanno T., Tsuchiya A., Shimizu T., Tanaka A., Nishizaki T. Indomethacin serves as a potential inhibitor of protein phosphatases. Cell. Physiol. Biochem. 2012, 30:1014-1022.
11. Tsuchiya A., Kanno T., Saito M., Miyoshi Y., Gotoh A., Nakano T., Nishizaki T. Intracellularly transported adenosine induces apoptosis in MCF-7 human breast cancer cells by accumulating AMID in the nucleus. Cancer Lett. 2012, 321:65-72.
12. Seshacharyulu P., Pandey P., Datta K., Batra S.K. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. 2013, 335:9-18.
13. Kurimchak A., Graña X. PP2A counterbalances phosphorylation of pRB and mitotic proteins by multiple CDKs: Potential implications for PP2A disruption in cancer. Genes Cancer 2012, 3:739-748.
14. Zhang Q., Claret F.X. Phosphatases: the new brakes for cancer development?. Enzyme Res. 2012, 659649. 10.1155/2012/659649.
15. Janssens V., Rebollo A. The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr. Mol. Med. 2012, 12:268-287.
16. Perrotti D., Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 2013, 14:e229-38. 10.1016/S1470-2045(12)70558-2.
17. Frémin C., Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J. Hematol. Oncol. 2010, 3:8. 10.1186/1756-8722-3-8.